P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

October 2007

Features

Physician–Patient Communication Concerning Medicare Part D In Two Midwestern States

In a survey conducted by the authors, physicians responded that even though they felt that it was not their responsibility to advise their senior patients on the government’s prescription drug benefit, many reported rendering such advice anyway.
Bruce Pitts, MD, MBA, Angela Dominelli, PhD, RPh, and Shamima Khan, MBA, PhD

Pharmaceutical Approval Update

Topics include the rivastigmine transdermal system (Exelon Patch) for mild-to-moderate dementia of the Alzheimer’s type and for mild-to-moderate dementia associated with Parkinson’s disease; armodafinil (Nuvigil) for improving wakefulness; and ambrisentan (Letairis) for pulmonary arterial hypertension.
Marvin M. Goldenberg, PhD, RPh, MS

Commentary

Blogging for Compliance

The blog called Master of Irony has the title that best sums up the changing nature of communication between doctors and patients: by posting their real feelings in cyberspace—away from the glare of the white lights and lab coats—bloggers have the potential to improve outcomes, compliance, and trust, in some cases all before uttering a single spoken word.
Miriam Reisman

Continuing Education Credit

Pharmacological Management of Behavioral Disturbance In Dementia

Dr. Casey reviews the causes of behavioral disturbance in patients with Alzheimer’s disease and other forms of dementia, with an emphasis on the various­ available therapies, including atypical antipsychotic agents, mood stabilizers­, antidepressants, benzodiazepines, and sleep medications.
David A. Casey, MD

Departments

Editorial

Too Good to Be True?

David Nash, MD, MBA, discusses a controversial report by Milliman, Inc., in which the costs of innovative therapies are considered relatively minor—too good to be true?
David B. Nash, MD, MBA

Medication Errors

Tubing for Blood Pressure Monitoring Devices­ Should Not Connect to IV Ports

Matthew Grissinger, RPh, FASCP, explains the problems that arise when tubing for blood pressure monitoring devices is inadvertently connected to an IV port.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Pharmacists Must Now Be Detectives: Is the Prescription Pad ‘Tamper-Proof’?

Stephen Barlas uncovers an additional duty that is being forced on pharmacists: making sure that prescription pads are “tamper­-proof.”
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From amiodarone to valproate, P&T presents the latest­ information about FDA approvals, new indications, and industry updates.

Drug Forecast

Ramoplanin: A Promising Treatment Option for Clostridium difficile–Associated Diarrhea and Vancomycin-Resistant Enterococcu­s

The authors discuss ramoplanin for Clostridium difficile– associated­ diarrhea and vancomycin­-resistant Enterococcu­s.
Christopher R. Emerson, PharmD, and Nino Marzella, BS, PharmD